• The October 26–30 inspection of the company’s clinical facility concluded without the issuance of a Form 483.

TORONTO, November 3, 2026 — BioPharma Services Inc. (BPSI) today announced the successful conclusion of an unannounced inspection by the U.S. Food and Drug Administration (FDA) at its clinical facility. The inspection took place from October 26 to 30, 2026, and concluded with no Form 483 observations issued.

“Successfully completing an unannounced FDA inspection with zero Form 483 observations is a proud moment for all of us at BioPharma Services,” said Vaideki Dharmaratnam, SVP, Quality & Compliance. “Inspection readiness is not something we prepare for only when an inspection is announced. It reflects the work we do every day, the quality systems we have built, and the commitment of our people.”

“Having led this inspection, I am extremely proud of how our teams came together, demonstrated their knowledge, and handled the process with confidence, professionalism, and transparency. This achievement reflects our strong quality culture, teamwork, and shared commitment to quality and compliance.”

The inspection recognized the efforts of BPSI’s teams across the clinical facility. The company remains committed to conducting clinical research with a focus on quality, compliance, data integrity, and participant safety.

About BioPharma Services Inc.

BioPharma Services Inc. is a full-service Contract Research Organization (CRO) specializing in the conduct of Phase 1/2a and Bioequivalence clinical trials for international pharmaceutical companies worldwide. With a focus on scientific integrity, operational excellence, and adaptive processes tailored to each client’s needs, BioPharma Services has established a reputation for delivering high-quality results in the pharmaceutical and biotech industries. The company’s multidisciplinary team of experts, state-of-the-art facilities, and commitment to innovation make it a trusted partner for pharmaceutical innovation and clinical research advancements. Headquartered in Toronto, Canada, BioPharma’s comprehensive services also include Bioanalysis at our GLP Certified Laboratory, Scientific and Regulatory Affairs, Biostatistics and Safety Data Analysis (CDISC), Data Management and Medical Writing. For more information about BioPharma Services and its clinical research capabilities, visit biopharmaservices.com.